U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07917338) titled 'Oral N-Acetylcysteine on Diabetic Macular Edema' on Oct. 28.
Brief Summary: Diabetic retinopathy (DR) is one of the leading causes of preventable visual impairment among working-age adults, with diabetic macular edema (DME) representing one of its most important vision-threatening complications. Diabetic macular edema develops when diabetes-associated retinal vascular dysfunction leads to disruption of the blood-retinal barrier (BRB), allowing fluid and plasma components to accumulate within the retinal tissue and impair macular function. The development and persistence of DME involve a complex interplay between vascular, inflammator...